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Abstract
Introduction The purpose of this study was to investigate the
effects of vegan diet in patients with rheumatoid arthritis (RA) on
blood lipids oxidized low-density lipoprotein (oxLDL) and natural
atheroprotective antibodies against phosphorylcholine (anti-
PCs).
Methods S i x t y - s i x  p a t i e n t s  w i t h  a c t i v e  R A  w e r e  r a n d o m l y
assigned to either a vegan diet free of gluten (38 patients) or a
well-balanced non-vegan diet (28 patients) for 1 year. Thirty
patients in the vegan group completed more than 3 months on
the diet regimen. Blood lipids were analyzed by routine methods,
and oxLDL and anti-PCs were analyzed by enzyme-linked
immunosorbent assay. Data and serum samples were obtained
at baseline and after 3 and 12 months.
Results Mean ages were 50.0 years for the vegan group and
50.8 years for controls. Gluten-free vegan diet induced lower
body mass index (BMI) and low-density lipoprotein (LDL) and
higher anti-PC IgM than control diet (p < 0.005). In the vegan
group, BMI, LDL, and cholesterol decreased after both 3 and 12
months (p < 0.01) and oxLDL after 3 months (p = 0.021) and
trendwise after 12 months (p = 0.090). Triglycerides and high-
density lipoprotein did not change. IgA anti-PC levels increased
after 3 months (p = 0.027) and IgM anti-PC levels increased
trendwise after 12 months (p = 0.057). There was no difference
in IgG anti-PC levels. In the control diet group, IgM anti-PC
levels decreased both after 3 and 12 months (p < 0.01). When
separating vegan patients into clinical responders and non-
responders at 12 months, the effects on oxLDL and anti-PC IgA
were seen only in responders (p < 0.05).
Conclusion A gluten-free vegan diet in RA induces changes
that are potentially atheroprotective and anti-inflammatory,
including decreased LDL and oxLDL levels and raised anti-PC
IgM and IgA levels.
Introduction
Patients with rheumatoid arthritis (RA) have increased cardio-
vascular disease (CVD) and mortality [1-3]. Several recent
studies indicate an increased prevalence not only of CVD but
also of atherosclerosis as determined by ultrasound of carotid
arteries [1,4,5]. The underlying mechanisms causing this
increased risk are not wholly clarified but inflammation and dis-
ease duration are suggested to be of importance [6-9]. Also,
extra-articular RA has been described as important in RA-
related mortality and CVD [10]. Patients with RA also have a
disturbed lipoprotein profile associated with disease activity
[11]. The dyslipidemia is often presented with normal or
decreased low-density lipoprotein (LDL) cholesterol, low high-
density lipoprotein (HDL) cholesterol, and high triglycerides
(TGs) in a manner comparable to inflammatory and infectious
diseases in general [12]. Treatment with disease-modifying
ACR = American College of Rheumatology; anti-PC = antibody against phosphorylcholine; aOxLDL = antibody against oxidized low-density lipopro-
tein; BMI = body mass index; BSA = bovine serum albumin; CRP = C-reactive protein; CVD = cardiovascular disease; DAS28 = Disease Activity 
Score in 28 joints; ELISA = enzyme-linked immunosorbent assay; ESR = erythrocyte sedimentation rate; FA = fatty acid; HAQ = Health Assessment 
Questionnaire; HDL = high-density lipoprotein; LDL = low-density lipoprotein; oxLDL = oxidized low-density lipoprotein; PAF = platelet-activating fac-
tor; PBS = phosphate-buffered saline; PC = phosphorylcholine; RA = rheumatoid arthritis; TG = triglyceride.Arthritis Research & Therapy    Vol 10 No 2    Elkan et al.
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anti-rheumatic drugs has been shown to improve lipid profile
in treatment responders but not in non-responders [4] and is
inversely correlated to changes of C-reactive protein (CRP)
and erythrocyte sedimentation rate (ESR) [13]. These results
suggest that the abnormal lipid levels are related to inflamma-
tion. On the other hand, treatment with long-term infliximab
surprisingly induced a pro-atherogenic profile despite reduced
inflammatory activity [14]. Another treatment that might affect
the dyslipidemia in RA is dietary manipulation such as potential
anti-inflammatory agents. The possibility that such manipula-
tion regulates the disturbed lipoprotein profile, however, has
been addressed less in RA. In this respect, vegan diet with a
low content of saturated fat and a higher intake of polyunsatu-
rated fat should be of special interest. Oxidized or other types
of modified LDL generally are believed to be of importance in
atherosclerosis and CVD since such LDL is taken up in the
artery wall by macrophages and has immune stimulatory and
pro-inflammatory properties [15,16]. We have focused on the
role of antibodies against PC (anti-PCs) and recently demon-
strated that high anti-PC IgM levels predict a favorable out-
come in the development of human atherosclerosis [17]. PC
is immunogenic when exposed to the immune system (for
example, in infectious agents, including Streptococcus pneu-
moniae and some nematodes). Anti-PCs belong to a group of
natural antibodies, which also are present in mice in the
absence of exposure to any microorganisms [18]. Earlier, we
have shown that a gluten-free vegan diet during 1 year signifi-
cantly reduced disease activity and decreased levels of anti-
bodies to beta-lacto globulin and gliadin in patients. with RA
[19]. In the present study, we addressed the effect of a gluten-
free vegan diet on risk factors, including blood lipids, oxidized
LDL (oxLDL), and anti-PCs for atherosclerosis.
Materials and methods
Patients
Sixty-six patients with RA according to the criteria of the Amer-
ican College of Rheumatology (ACR) [20] were enrolled into
the study as previously described [19]. In brief, they were eli-
gible for inclusion if they were between 20 and 69 years of
age, had a disease duration of between 2 and 10 years, had
not tried dietary manipulation before, and had active disease.
Active disease was considered present if the patients fulfilled
two of the following three criteria: duration of early morning
stiffness of at least 1 hour, ESR of at least 30 mm, and six or
more swollen and/or tender joints. Exclusion criteria were cur-
rent malignancy; severe cardiovascular, pulmonary, or renal
disease; and diabetes mellitus. Patients were allowed to con-
tinue on non-steroidal anti-inflammatory drugs, oral glucocorti-
coids, and anti-rheumatic therapy. If necessary, these
medications could be changed during the study. Thus, two
patients in the vegan group and one in the non-vegan group
started anti-rheumatic therapy during the study period. None
of the patients used statins or biologic medications before or
during the study. All patients received an addition of 1 mg/day
of vitamin B12 and 50 μg/day of selenium. The patients were
randomly assigned to two different diets, either a vegan diet
free of gluten or a non-vegan diet for 1 year, using a minimiza-
tion technique as described [19]. This randomization tech-
nique was used to avoid an imbalance in the following
variables: age, disease duration, and concomitant anti-rheu-
matic treatment [19]. The study was approved by the Karolin-
ska University Hospital ethics committee and was performed
in accordance with the Declaration of Helsinki. We received
informed consent from the patients.
Study diets
Vegan diet free of gluten, called vegan diet
The patients randomly assigned to a vegan diet (n = 38)
started with 1-day low-energy fasting, with vegetable broth
and berry juices, followed by the gluten-free vegan diet for 1
year. In the vegan diet, protein energy level was 10% of the
total energy intake, the carbohydrates 60%, and fat 30%. The
vegan diet contained vegetables, root vegetables, nuts, and
fruits. As gluten was not permitted, the diet contained buck-
wheat, millet, corn, rice, and sunflower seeds. Unshelled ses-
ame seeds in the form of sesame milk were a daily source of
calcium.
Well-balanced diet, called non-vegan diet
In all, 28 patients were randomly assigned to a well-defined
non-vegan diet. This diet contained 10% to 15% protein, 55%
to 60% carbohydrate, and no more than 30% fat, of which sat-
urated fat was not supposed to make up more than 10% of the
total energy intake. This implies a variety of foods from all food
groups. Five or more daily servings of fruits and vegetables
were recommended as well as increasing intakes of starch
and other complex carbohydrates by eating potatoes, bread,
and cereals and selecting whole-grain products as often as
possible [19].
Dietary intake follow-up
The introductory intervention period lasted 6 to 7 days for both
groups. During that period, the patients received instructions
in the theory and practical preparation of the diet in question.
Thereafter, each patient had access to advice and help from
one of two physicians, a dietician, and nurses in maintaining
the respective diet. Follow-up meetings with the different
groups, which focused on providing support and advice from
the dietician and the nurse, took place at 3, 6, 9, and 12
months. Dietary compliance was assessed by 3-day food
intake records at baseline and at 3, 6, 9, and 12 months. Fur-
thermore, at each visit to the clinic, the patients were ques-
tioned about compliance with the study diet. Also, between
visits, the nurse made phone calls to the patients and the
patients had the opportunity to call the nurse when needed.
Assessments
Body mass index (BMI) was calculated from weight divided by
the square of the height (kg/m2). Individuals with BMI values of
less than 18.5 kg/m2 were classified as underweight/malnour-Available online http://arthritis-research.com/content/10/2/R34
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ished, between 18.5 and 24.9 kg/m2 as normal, 25 and 29.9
kg/m2 as overweight, and greater than 30 kg/m2 as obese
[21].
Disease activity
Disease activity was assessed by the composite index Dis-
ease Activity Score in 28 joints (DAS28), which includes
number of swollen joints, number of tender joints, patient's
assessment of global disease activity, and ESR [22]. At 3 and
12 months, EULAR (European League Against Rheumatism)
response criteria were recorded [23]. Good responders were
those with a DAS28 improvement of at least 1.2 and an end-
point value of less than 3.2. Moderate responders were
patients with either an improvement of at least 1.2, independ-
ent of the attending DAS28 value, or an improvement of at
least 0.6 in combination with an endpoint DAS28 of less than
5.1. Also, the ACR 20% response was determined for each
patient [24].
Physical function
The Swedish version of the Stanford Health Assessment
Questionnaire (HAQ) was used to measure physical function
[25]. The HAQ score ranges from 0 to 3, with a higher score
indicating a higher degree of disability.
Analytical methods
At baseline, before initiation of the diets, and after 3 months
and 1 year, blood samples were drawn in the morning after an
overnight fast. The biochemical variables were determined
automatically by standard laboratory methods with commercial
kits. They included ESR, CRP, hemoglobin, white blood count,
serum albumin, total cholesterol, LDL, HDL, and TGs. The lip-
ids were considered pathologic when cholesterol was greater
than 5.0 mmol/L, LDL greater than 3.0 mmol/L, TGs greater
than 2.0 mmol/L, HDL less than 1.0 mmol/L (for men), and
HDL less than 1.2 mmol/L (for women). Serum samples were
also stored at -70°C until analyzed for oxLDL and natural anti-
PCs.
Oxidized low-density lipoprotein and antibody 
determinations
OxLDL was determined by use of a commercial kit (Mercodia
AB, Uppsala, Sweden) as described by the manufacturer.
Antibodies to PC-bovine serum albumin (BSA) were deter-
mined by enzyme-linked immunosorbent assay (ELISA) essen-
tially as described [26]. Briefly, pooled serum from medium- to
high-titer individuals was used as an internal standard and was
tested on every plate. The plateau of antibody binding was
reached with the antigen concentration of 10 μg/mL. An F96
microtiter polysorp plate, therefore, was coated with PC-BSA
(10 μg/mL) 50 μL/well in phosphate-buffered saline (PBS).
Coated plates were incubated overnight at 4°C. After five
washings with PBS, the plates were blocked with 2% BSA-
PBS for 2 hours at room temperature and washed as
described above. Serum samples were diluted (1:30) in 0.2%
BSA-PBS and added at 50 μL/well. Plates were incubated
overnight at 4°C and washed as described above. Alkaline
phosphatase-conjugated goat anti-human IgM, IgA, or IgG
(diluted 1:7,000 in the sample buffer) was added at 100 μL/
well and incubated at 4°C overnight. After five washings, color
was developed by adding the alkaline phosphatase substrate
(p-nitrophenyl phosphate) at 100 μL/well and incubating the
plates for 60 minutes at room temperature in the dark. The
plates were read in an ELISA Multiscan Plus spectrophotom-
eter (EMax; Molecular Devices, Sunnyvale, CA, USA) at 405
nm. All samples were measured in duplicates in a single assay,
and the coefficients of variation were below 10% to 15%.
Statistical analyses
The statistics were computed using StatView software (SAS
Institute AB, Stockholm, Sweden). Correlation analysis was
performed using simple regression for normally distributed var-
iables, and Spearman correlation analysis for non-normally dis-
tributed variables. Skewed continuous variables were
logarithmically transformed to attain a normal distribution.
Study groups were compared using analysis of variance
repeated measurements. Effects within groups were com-
pared using the Student t test. The significance level was put
at a p value of less than 0.05.
Results
Thirty patients in the vegan group and 28 in the non-vegan
group completed at least 3 months on the diet regimen and
were included in our analyses. Additionally, 8 patients in the
vegan group stopped the diet before completing 12 months.
The two diet groups were well balanced in regard to patient
characteristics and disease activity (Table 1). Furthermore,
there were no differences between groups for the metabolic
and lipid variables tested except that HDL was higher at base-
line among the vegan group as compared with the non-vegan
diet group (p = 0.03). Of the patients, 45% had pathologic lev-
els of cholesterol, 47% of LDL, 30% of HDL, and 7% of TGs.
When effects of the different diet regimens were compared
between groups at 12 months, BMI (F = 6.6, p = 0.0024),
weight (F = 8.9, p = 0.003), and LDL (F = 18.8, p < 0.0001)
were significantly lower and anti-PC IgM (F = 8.0, p = 0.0006)
was higher in the vegan diet group whereas the increase in
anti-PC IgA and decrease in oxLDL differed only trendwise (F
= 2.5, p = 0.084 and F = 2.6, p = 0.081, respectively). DAS28
was higher in the diet control group than in the vegan group (F
= 3.1, p  = 0.047), whereas HAQ score did not differ
significantly.
The vegan group patients reduced their weights from 66.4
(61.7 to 71.1) kg at baseline to 62.2 (58.2 to 66.2) kg at the
12-month visit (p < 0.001) and BMI from 24.1 (22.3 to 25.9)
to 22.7 (21.3 to 24.2) (p < 0.001). The corresponding figures
for the non-vegan diet group were 67.8 (61.9 to 73.7) kg to
67.1 (60.8 to 73.5) kg and 23.8 (21.6 to 36.0) to 23.4 (20.9
to 25.9), respectively (both non-significant changes).Arthritis Research & Therapy    Vol 10 No 2    Elkan et al.
Page 4 of 8
(page number not for citation purposes)
In the vegan group, DAS28 and HAQ score were significantly
reduced at both 3 and 12 months compared with baseline and
CRP at 12 months (Table 2). Among the non-vegan diet
group, DAS28 showed a slight but significant decrease at 3
months but not at 12 months, whereas HAQ score and CRP
were unchanged over time (Table 2). In the vegan group, 63%
were good and moderate responders at 12 months compared
with 32% of the non-vegan diet patients. The ACR 20%
responses were 37% and 4%, respectively. In the vegan
group, total cholesterol, LDL, and the ratio LDL/HDL
decreased significantly after both 3 and 12 months, whereas
TGs and HDL did not change (Table 2). These changes were
seen both in responders and non-responders (data not
shown). OxLDL levels decreased significantly after 3 months
and trendwise after 12 months (Table 2). When patients were
separated into ACR 20% responders and non-responders at
12 months, the decrease in oxLDL was seen only in respond-
ers and was significant at both 3 and 12 months (p < 0.01).
IgM anti-PC levels were raised after 3 and 12 months com-
pared with baseline, but the difference reached a trendwise
significance only at 12 months (p = 0.057). IgA anti-PC levels
were higher at 3 months compared with baseline (p = 0.020)
but were only non-significantly higher after 12 months. There
was no difference in IgG anti-PC levels between any time
points during the study. Low levels of anti-PC IgM (below 25%
percentile) were more common in the non-vegan group than in
the vegan group after 3 months (p < 0.038). In the non-vegan
diet group, HDL was increased significantly after 3 months (p
< 0.05) and non-significantly after 12 months, whereas other
lipids did not change (Table 2). IgM anti-PC levels decreased
significantly both after 3 and 12 months (p < 0.001). Other
antibodies tested did not differ.
Discussion
Here, we report that a gluten-free vegan diet in patients with
RA induced a decrease in total cholesterol, LDL, and the ratio
LDL/HDL whereas TGs and HDL did not change significantly.
In contrast, the balanced diet in the control group did not influ-
ence lipid values significantly. There is now a large body of evi-
dence indicating that this change of lipid profile is favorable in
relation to atherosclerosis and CVD, and this diet therefore is
likely to be antiatherogenic also in RA. We also report that
both BMI and weight decreased significantly in the vegan diet
group, which was not the case in the control group. Choles-
terol, LDL, and BMI also differed significantly between groups
and not only within the vegan group.
These findings are compatible with previous results of vegetar-
ian/vegan dietary regimens in non-RA subjects which have
shown lower blood pressure, lower BMI, and lower incidence
of CVD [27-29]. Furthermore, these individuals had lower total
cholesterol and lower LDL [30,31]. When matched for BMI,
subjects on a vegetarian diet had a body fat percentage similar
to that of omnivore subjects [32]. Further evidence for the
importance of diets on lipoprotein profile is the low incidence
of myocardial infarction in Greenland Eskimos, whose high-fat
diet is rich in marine lipids [33,34].
In the vegan group, neither the levels of cholesterol, LDL, and
the ratio LDL/HDL nor the changes differed between respond-
ers and non-responders (in contrast to oxLDL) nor were there
any correlations between these changes and inflammatory
activity. Such independence of inflammatory activity is similar
to that reported concerning changes of linoleic acid found dur-
ing vegan and vegetarian diets [35]. This implies that the
change in lipid profile was a consequence of the vegan diet
and not a result of reduced inflammatory activity and that the
Table 1
Patient characteristics for the two diet groups at baseline
Vegan diet n = 30 Non-vegan diet n = 28 P value
Patients, female/male, n 28/2 24/4
Age in years, mean (CI) 49.9 (46.6–53.3) 50.8 (46.2–55.5) 0.75
Disease duration in years, mean (CI) 5.0 (4.1–6.0) 5.8 (4.7–6.9) 0.31
Rheumatoid factor-positive, n (%) 25 (83) 21 (75)
Body mass index, kg/m2, mean (CI) 24.1 (22.3–25.9) 23.8 (21.6–26.0) 0.81
Weight, kg, mean (CI) 66.4 (61.7–71,1) 67.9 (61.9–73.7) 0.70
DAS28, mean (CI) 5.3 (5.0–5.7) 5.3 (4.9–5.6) 0.80
HAQ score, mean (CI) 1.4 (1.2–1.5) 1.3 (1.1–1.5) 0.44
Patients on DMARDs, n (%) 26 (87) 26 (93)
Patients on glucocorticoids, n (%) 18 (60) 9 (32)
Patients on NSAIDs, n (%) 24 (80) 24 (86)
P values are difference between groups. CI, confidence interval; DAS28, Disease Activity Score in 28 joints; DMARD, disease modifying anti-
rheumatic drug; HAQ, Health Assessment Questionnaire; NSAID, non-steroid anti-inflammatory drug.Available online http://arthritis-research.com/content/10/2/R34
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change in lipids did not have any impact on disease activity in
RA.
In contrast to LDL and cholesterol values, TGs did not change
as a consequence of vegan diet. In systemic lupus erythema-
tosus, we have reported that high TGs are characteristic of
this rheumatic disease and that TGs are strongly associated
with disease activity and inflammation) [36,37]. The dyslipi-
demia in RA therefore may differ somewhat from the 'lupus
pattern of dyslipidemia', in which there appears to be a clearer
association with inflammation.
Another finding herein is that levels of circulating oxLDL
decreased in the vegan group, which was not the case among
controls. OxLDL stimulates endothelial and monocyte adhe-
siveness [38,39] and is taken up by macrophages in the artery
wall, which develop into foam cells [40]. OxLDL itself, or oth-
erwise modified LDL, also has many pro-inflammatory and
immune stimulatory properties, including activation of T cells
[41] and monocytes/macrophages [39]. Therefore, it is possi-
ble that the reduction in oxLDL also could contribute to the
decreased disease activity due to its anti-inflammatory proper-
ties, a possibility supported by the finding that the reduction of
oxLDL was seen only in diet responders.
One important mechanism by which oxLDL promotes immune
activation is through platelet-activating factor (PAF), PAF-like
lipids, and lysophosphatidylcholine in oxLDL which have PC
as one determining epitope [42-44]. Furthermore, oxLDL is
taken up by macrophages through scavenger receptors,
including CD36, which has PC as ligand [45]. Circulating
oxLDL has been reported to be a risk marker for CVD and
atherosclerosis [46], and decreased levels of oxLDL thus
could contribute to a less atherogenic profile. Little is known
about a possible role of oxLDL in promoting the chronic inflam-
mation present in RA, but it is interesting to note that oxLDL is
present in foam cells in synovia from patients with RA [47],
indicating that oxLDL also could play a role in the pathogene-
sis of RA.
Antibodies against OxLDL (aOxLDLs) are raised in RA, but
their clinical importance for CVD and atherosclerosis has been
Table 2
Disease activity and lipid variables for the patients who followed the diet regimens for at least 3 months
Vegan diet patients Non-vegan diet patients
Baseline 3 months P value 12 months P value Baseline 3 months P value 12 months P value
DAS28a 5.3 
(5.0–5.7)
4.7
 (4.3–5.2)
0.002 4.3
 (3.8–4.9)
<0.001 5.3
 (4.9–5.6)
5.0 
(4.6–5.3)
0.014 5.0 
(4.6–5.4)
0.19
HAQ scorea 1.4 
(1.2–1.5)
1.1 
(0.9–1.3)
0.010 1.0 
(0.8–1.2)
0.001 1.3 
(1.1–1.5)
1.2
 (1.0–1.4)
0.62 1.2
 (1.0–1.4)
0.59
CRPb 13 
(6–26)
11
 (5–29)
0.68 5
 (4–20)
0.008 22 
(5–32)
10
 (5–33)
0.07 12 
(4–19)
0.28
Albumina 36 
(34–37)
34 
(33–35)
0.013 36
 (35–38)
0.43 35
 (34–37)
37 
(35–39)
0.06 37 
(35–38)
0.06
Cholesterolb 5.2 (4.4–5.7) 4.3 
(3.9–5.0)
<0.001 4.3
 (3.8–5.1)
0.003 4.7 
(4.2–5.3)
5.1 
(4.3–5.5)
0.20 5.0
 (4.0–5.5)
0.68
Triglyceridesa 1.1
 (1.0–1.3)
1.2 
(1.0–1.3)
0.43 1.1
 (0.9–1.2)
0.32 1.1
 (0.9–1.5)
1.2 
(0.7–1.6)
0.79 1.1
 (0.8–1.3)
0.69
HDLa 1.4
(1.3–1.5)
1.3 
(1.2–1.4)
0.14 1.4
 (1.3–1.6)
0.22 1.3
 (1.2–1.3)
1.3
 (1.2–1.4)
0.045 1.3 
(1.2–1.4)
0.07
LDLb 3.2
 (2.6–3.7)
1.3 
(1.2–1.6)
<0.001 2.4 
(2.1–3.0)
<0.001 2.9
 (2.5–3.4)
3.1
(1.2–1.5)
0.23 3.2 
(2.4–3.5)
0.83
LDL/HDLa 2.7
 (2.2–3.1)
2.0 
(1.8–2.3)
<0.001 1.9
 (1.6–2.2)
<0.001 2.4
 (2.2–2.7)
2.5
 (2.2–2.7)
1.00 2.2
 (2.0–2.5)
0.22
oxLDLa 54.7 
(46.2–63.2)
49.4 
(43.0–55.8)
0.021 48.6 
(41.7–56.5)
0.09 54.5 
(45.9–63.1)
54.8 
(46.2–63.4)
0.88 55.2 
(45.6–64.7)
0.57
anti-PC, IgMa 778 
(706–849)
812 
(729–896)
0.39 822 
(743–900)
0.057 797 
(676–918)
742 
(620–864)
<0.001 731 
(596–870)
0.003
anti-PC, IgGa 861 
(761–962)
879 
(785–974)
0.28 859
 (760–957)
0.92 913 
(814–1012)
900 
(802–999)
0.46 880 
(764–996)
0.47
anti-PC, IgAa 837
 (588–1087)
938 
(640–1234)
0.027 854 
(595–1112)
0.26 0.62 798
 (567–1030)
772 
(539–1005)
0.17 745
 (357–1028)
0.42
aMean values (confidence interval 95%). bMedian values (25th to 75th percentile). P values are differences between baseline and 3 and 12 
months, respectively, for each diet group. Anti-PC, antibody against phosphorylcholine; CRP, C-reactive protein; DAS28, Disease Activity Score 
in 28 joints; HAQ, Health Assessment Questionnaire; HDL, high-density lipoprotein; LDL, low-density lipoprotein; oxLDL, oxidized low-density 
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much discussed [48,49]. Initially, aOxLDLs were reported to
be pro-atherogenic, but subsequent studies suggest that at
least at an early stage of disease they could in fact be anti-
atherogenic [48,50-52]. This latter possibility is supported by
animal experiments from several groups in which immunization
with oxLDL causes decreased atherosclerosis development.
Varying results may also depend on the fact that LDL oxidation
is difficult to standardize [15,50].
Instead of aOxLDLs, we have focused on anti-PCs, and one
major finding is that anti-PC levels of IgM and IgA subclasses
were raised after a vegan diet. Low levels of anti-PC IgM were
more common in the control group than among vegans. Anti-
PC IgM was also significantly higher in the vegan group as
compared with the control diet group, whereas there was only
a trendwise increase in anti-PC IgA.
We recently reported that there is an inverse correlation
between anti-PC IgM levels and atherosclerosis development
in humans [17]. Further to this, low levels of anti-PC IgM pre-
dict an increased risk of CVD in a population-based study
(Frostegård et al, unpublished observation). Furthermore, ani-
mal experiments indicate that administration of anti-PCs amel-
iorates atherosclerosis development [53]. These changes in
anti-PC levels which were induced by a vegan diet thus are
likely to be antiatherogenic, although the role of anti-PC IgA in
this respect has been less studied. PC is known to be immu-
nogenic and present on important human pathogens like S.
pneumoniae  [18], and apoptotic cells expose this antigen,
which is normally cryptic [54].
Earlier, we reported a decrease in serum levels of IgG antibod-
ies to gliadin and β-lactoglobulin in the group of patients who
responded positively to the vegan diet but not in other patients
[19]. This reduction was suggested to be explained by dimin-
ished immune response to exogenous food antigens. In con-
trast, anti-PC was thus raised after a vegan diet. The cause of
this increased response is not clear. However, we recently
reported that anti-PC IgM is much lower in a Swedish popula-
tion than in individuals from New Guinea living a traditional life
as horticulturalists [55]. Their food contains much less of dairy
products, refined fat, and grain-derived food and much more
of fish, vegetables, and roots. We found that, in this popula-
tion, anti-PC IgM levels were associated with a polyunsatu-
rated fatty acid (FA) dihomo-gama-linolic acid 20:3 n-6, and
we hypothesized that exposure to easily oxidized FA (for exam-
ple, in the gut immune system) could elicit more robust anti-PC
IgM and IgA levels in contrast to saturated FAs, which are not
oxidized. Further studies are needed to clarify whether such a
mechanism could be of importance. Hypothetically, the gut
flora could be changed and so too could exposure of PC,
another possibility that deserves further studies. Whether glu-
ten plays a role in the effects presented herein remains to be
elucidated.
Our preliminary experiments indicate that polyclonal human
anti-PCs of the IgM subclass can inhibit uptake of oxLDL in
macrophages and also inhibit pro-inflammatory effects medi-
ated by PAF-like lipids generated during LDL oxidation (Frost-
egård et al. unpublished observation). Some of these effects
thus could be anti-inflammatory, at least in the context of
chronic inflammation. In principle, anti-PCs could play a role
also in chronic inflammation as protective antibodies in general
as in RA and be developed into novel treatment modalities in
addition to other protective antibodies discussed in RA [56].
The vegan group also showed significantly lower levels of
CRP, a physiologic marker of subclinical inflammation, which
has been shown to be associated with insulin resistance and
CVD [57,58]. Elevated levels of CRP have been suggested to
reflect overproduction by expanded adipose tissue mass [57].
In line with our previous findings [19], both DAS28 and HAQ
decreased in the vegan group whereas only DAS28 at 3
months decreased in the control diet group.
Some limitations in the present study should be considered.
First, a small number of patients participated. Nonetheless, the
size of our groups was sufficient to detect several differences
between diet groups, but we could not exclude the possibility
of even more differences if a larger number had been studied.
Second, a long-term diet study always poses special ques-
tions concerning compliance. The fact that compliance was
monitored both via regular contacts between the patients and
staff of the project and via dietary intake records made us con-
fident that compliance to diet was high among the patients in
both the vegan and non-vegan groups. The change in anti-
rheumatic medication was considered too limited to have any
consequences for results.
Conclusion
A vegan diet in RA induced decreased LDL and oxLDL levels
and raised levels of natural antibodies of IgA and IgM sub-
classes to PC. We hypothesize that these changes are
atheroprotective since LDL is atherogenic and oxLDL has
immune-stimulatory and pro-inflammatory effects in athero-
sclerosis. Furthermore, anti-PC levels are negatively associ-
ated with the development of atherosclerosis. To further clarify
which components of a vegan diet and which underlying
mechanisms that contribute to the effects described here is
therefore of interest both in the context of CVD in RA, and in
RA in general, where diet intervention as here has an amelio-
rating effects in many patients.
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